Topic

CagriSema

A collection of 2 issues

Novo Nordisk Shares Fall on CagriSema Trial Setback

Novo Nordisk's stock experienced a decline following underwhelming results from the CagriSema trial, impacting investor sentiment. Stay updated with the latest insights.

Novo Nordisk's CagriSema Shows 23% Weight Loss in Trials

Novo Nordisk's CagriSema demonstrates 23% weight loss in clinical trials, slightly below expectations. Explore its potential impact on weight management solutions.